Author:
Scott Brandon,Zhang Kelly,Yehl Peter,Yang Samuel
Reference21 articles.
1. Preclinical in vivo ADME studies in drug development: A critical review;M Pellegatti;Expert Opinion on Drug Metabolism and Toxicology,2012
2. Guidance for Industry M3(R2) Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals;International Consortium of Harmonisation (ICH) ICH M3,2010
3. Mass balance, metabolic disposition, and pharmacokinetics of [14C]ensartinib, a novel potent anaplastic lymphoma kinase (ALK) inhibitor, in healthy subjects following oral administration;S Zhou;Cancer Chemotherapy and Pharmacology,2020
4. Mass balance and metabolite profiling of 14Cguadecitabine in patients with advanced cancer;J Roosendaal;Investigational New Drugs,2020